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Abstract 
Introduction: It remains unclear whether offering psychiatric patients their preferred treatment 
influences outcomes at the symptom level. 
Objective: To assess whether offering patients with Panic Disorder with/without Agoraphobia (PD/A) 
a choice between two psychotherapies yields superior outcomes to random assignment.  
Methods: In a doubly randomised, controlled preference trial (DRCPT), 221 adults with PD/A were 
randomly assigned to: choosing Panic-Focused Psychodynamic Therapy (PFPP) or Panic Control 
Treatment (PCT; a form of CBT); random assignment to PFPP or PCT; or wait-list control.  Primary 
outcomes were PD/A severity, work status and absences at post-treatment. Outcomes at post-
treatment, 6-, 12- and 24-month follow-ups were assessed using segmented multilevel linear growth 
models.   
Results: At post-treatment, the choice and random conditions were superior to the control for panic 
severity but not work status/absences. The choice and random conditions did not differ during 
treatment or follow-up for the primary outcomes. For panic severity, PCT was superior to PFPP 
during treatment (SMD = -0.64; 95% CI = -1.02 to -0.25); PFPP was superior to PCT during follow-up 
(SMD = 0.62; 95% CI = 0.27 to 0.98). There was no allocation by treatment type interaction (SMD = -
0.57; 95% CI = -1.31 to 0.17).  
Conclusions: Previous studies have found that offering patients their preferred treatment yields small 
to moderate effects but have not employed designs that could rigorously test preference effects.  In 
this first DRCPT of two evidenced-based psychotherapies, allowing patients with PD/A to choose 
their preferred treatment was not associated with improved outcomes. Further DRCPTs are needed.  
 
 
Trial Registration 
ClinicalTrials.gov identifier: NCT01606592 
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Introduction 
Shared Decision Making (SDM) is part of an overall strategy to improve health outcomes [1]. An 
important aspect of SDM is providing patients with information about the available treatments and 
encouraging them to choose the treatment they prefer. Although there is evidence that SDM 
improves patient knowledge about treatment options, and increases their sense of involvement in 
their healthcare, the effects of SDM on health outcomes at the symptom/syndrome level remain 
unclear [1]. Across studies where patients with psychiatric disorders are offered a choice between 
two or more treatments, meta-analyses have found that a majority express a preference for 
psychotherapy over pharmacotherapy, with those receiving their preferred treatment being less 
likely to drop out, reporting higher treatment satisfaction, and experiencing marginally better clinical 
outcomes [2-4]. Of note, the majority of studies included in these meta-analyses compared 
pharmacotherapy to psychotherapy for depression, and the conclusions that could be drawn were 
significantly limited by heterogeneity across the included studies [5]. The effect size attributable to 
receiving one’s preferred treatment has been estimated at Cohen’s d = 0.15 – 0.31 [6, 7, 2, 3], and d 
= 0.49 for anxiety disorders specifically [7].  
     Panic Disorder with or without Agoraphobia (PD/A) is a commonly occurring condition with a 
lifetime prevalence of 1.7% to 4%; associated with high rates of comorbidity, an increased risk of 
morbidity and mortality, a heavy burden on the family, diminished work capacity, and increased 
healthcare utilization [8]. Meta-analyses by the Cochrane organization find that pharmacotherapies 
and psychotherapies (mostly antidepressants and cognitive behavioural therapies - CBT), either alone 
or in combination, yield moderate to large effect sizes relative to no/minimal treatment, and small to 
medium effect sizes relative to placebo or other psychological treatments, in terms of short-term 
remission [9-11]. However, the use of pharmacotherapy is associated with a significantly increased 
risk of attrition during treatment and relapse when treatment is discontinued [11]. A recent network 
meta-analysis of psychological therapies for PD/A failed to find unequivocal evidence of the 
superiority of any treatment, although CBT, followed by psychodynamic therapy (PDT), had the best 
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evidence of short-term efficacy, with the latter showing slightly better tolerability [10]. Of further 
importance in the treatment of PD/A is the stability of change after treatment termination. A recent 
meta-analysis of long-term outcomes in CBT for anxiety disorders found significant further 
improvement up to 12 months after treatment with PD patients [12]. The longer-term efficacy of PDT 
for anxiety disorders, and PD/A specifically, remains unclear [13].  
In view of the research on patient preferences, offering adults with PD/A their preferred 
treatment may be associated with improved outcomes. A doubly randomised controlled preference 
(DRCPT) design [14], in which participants are randomised to self-selection or random assignment of 
treatment conditions, would test this hypothesis. To date, no DRCPTs have been conducted to 
examine preference effects for any form of PD/A treatment, or indeed between any two forms of 
psychotherapy for any psychiatric disorder.  
Using a DRCPT design, the primary aim of the present study was to evaluate short- and long-
term change for participants with PD/A treated with CBT or PDT under self-selected versus 
randomised allocation to treatment conditions. The treatment alternatives were Panic Control 
Treatment (PCT) [15, 16], the CBT approach with the largest evidence base for PD/A, and PFPP [17, 
16], the PDT approach with the largest evidence base for PD/A. Our hypotheses were that for 
clinician-rated PD/A severity: 1) outcomes in the treatment groups would be superior to Control at 
post-treatment; 2) outcomes for participants who chose their treatment, irrespective of treatment 
type, would be superior to those of participants randomly assigned to treatment; and 3) PCT would 
yield superior outcomes to PFPP. Additional primary (occupational status, PD/A-related absences 
from work) and secondary outcomes (mobility, depression and functional impairment) were assessed 
but no a priori hypotheses tested. Finally, and in an exploratory way, we test whether there is an 
interaction effect between treatment allocation and treatment types on outcome. 
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Materials and Methods 
Study design and participants 
The Psychotherapy Outcome and Self-selection effects project (Project POSE) was a multicentre, 
DRCPT of PCT and PFPP for PD/A. Participants were randomly allocated to self-selection/choice of 
treatment (Choice; C), random assignment to treatment (Random; R), or to a wait-list control 
condition (Control). Participants allocated to Choice were provided written information about the 
two treatments and then asked to choose either PCT (CPCT) or PFPP (CPFPP). Participants allocated 
to Random were randomly allocated to PCT (RPCT) or PFPP (RPFPP). Participants allocated to Control 
were re-randomised to either the Choice or Random conditions at the end of the 3-month Control. 
Although wait-list controls have been found to be of limited value in trials evaluating the efficacy of a 
treatment [18], this was not strictly a wait-list group.  The primary aim of this trial was to evaluate 
the relative efficacy of random assignment to two types of treatment type (Random) versus the 
patient choosing their preferred option from the same two treatment types (Choice). The wait-list 
condition was included to control for the possibility that both the randomly assigned and chosen 
treatments were equally ineffective in treating symptoms of PD/A. Further details of the study are 
presented in the published trial protocol [19]. 
     The trial was carried out in four regions in Sweden at outpatient psychiatry, primary health care, 
and youth guidance clinics. Inclusion criteria were: 1) aged 18 to 702 years; 2) current principal DSM-
IV diagnosis of PD/A, including at least one panic attack per week during the three weeks preceding 
trial assessment; 3) if medicated, staying on a stable dose for at least one month prior to trial 
inclusion; 4) willing to keep medication dosage stable throughout the trial treatment phase; 5) not 
currently engaged in psychotherapy and willing to refrain from starting new treatments during the 
treatment phase; 6) ability to complete the treatment phase within 16 weeks; and 7) if participants 
actively avoided situations that caused them panic, they had to: 1) score ≥ 5 on an apprehension 
                                                             
2 At CONSORT registration inclusion criteria was “aged 18-60 years”. However, before inclusion 
commencement this inclusion criterion was changed in order not to exclude individuals who were still actively 
working between 60 and 70 years of age. 
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question about having a panic attack from the Anxiety Disorder Interview Schedule for DSM-IV[20] 
and: 2) score ≥ 4 on at least one question from the Avoidance-Alone Subscale of the Mobility 
Inventory for Agoraphobia [21]. Exclusion criteria were: 1) a current substance abuse/dependence 
disorder (or in remission for ≤12 months prior to trial inclusion); 2) current psychosis, delusions, 
mania, or Autism diagnosis; 3) acutely suicidal; 4) a history and current presentation of at least one 
clinically significant medical condition sufficient to cause cognitive or physical impairments that 
might prevent full participation in treatment; and 5) active involvement in a legal dispute related to 
their mental health. 
     Trial information was made available via a Project POSE website and advertisements. In addition, 
clinic staff provided trial information to patients who suffered from anxiety and panic. Interested 
individuals could also self-refer or be referred by their local mental health care provider. Individuals 
who expressed an interest were pre-screened for eligibility by phone and, if suitable, invited to a 
face-to-face diagnostic interview. All results are reported according to CONSORT guidelines [22]. 
Randomisation and masking 
The allocation ratio to the Choice, Random and Control conditions was 4:4:1. At the end of the three-
month Control condition, the re-allocation ratio to the Choice and Random conditions was 1:1. 
Participants were allocated to the Choice, Random, and Control conditions at each clinic. For the 
Random condition, a stratification procedure was used so that equal numbers of participants were 
allocated to PFPP and PCT at each clinic. Randomisation was done using the software Research 
Randomizer [23]. In the Choice condition, participants were provided separate, 500-word written 
descriptions of the two treatments (PCT and PFPP) before indicating their treatment preference. The 
treatment descriptions were blinded (did not specify the name of the treatment), specific, well 
balanced, and easy-to-read presentations of PCT and PFPP, that had been piloted before the study 
commenced. Each treatment description was comprised of three headed sections: 1) How is panic 
disorder viewed in treatment; 2) How do you work in treatment; and 3) What results can I expect. For 
PCT, the sections described: 1) the role of fear of fear (bodily reactions) in the development of panic; 
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2) learning [with the therapist] how to change cognitions and behaviours in relation to panic triggers 
and exposure to situations that trigger panic; and 3) a better understanding of how to change 
cognitions/behaviours that increase the likelihood of panic attacks will be accompanied by a 
reduction in their frequency and greater functionality. For PFPP, the sections described: 1) the 
potential role of negative life events in the onset of panic attacks, and the effects of the latter on 
emotional functioning and relationships; 2) exploring [with the therapist] the causes of the panic 
attacks and their effects on emotions/relationships; and 3) a better understanding of the causes of 
panic attacks and their effects on emotions/relationships will be accompanied by reduced feelings of 
vulnerability, less frequent panic attacks and greater functionality. The full treatment descriptions 
are available from the authors upon request. 
Interventions 
PCT [15] is a manualized, individual cognitive-behavioural treatment for adults with PD/A. In this 
trial, PCT comprised 12-14 sessions, completed in 10-16 weeks, with the first week including two 
sessions and subsequent weeks one session each. Sessions were 60 minutes in length and extended 
to 90-120 minutes for sessions involving therapist-led exposure (total treatment duration = 780-1140 
minutes). PCT involves: psychoeducation about the nature of PD and agoraphobia and training in 
self-monitoring of symptoms (sessions 1-2); building a hierarchy of agoraphobic situations (session 
3); breathing retraining (session 4); cognitive restructuring techniques (sessions 4-6); in vivo exposure 
(sessions 6-13); and relapse prevention (session 14). Between-session homework assignments, done 
throughout treatment, involved symptom self-monitoring and after the first session involving 
therapist-led exposure, planned patient-led exposures. 
     PFPP [17] is a manualized, individual psychodynamic treatment for adults with PD/A. In this trial, 
PFPP comprised 19-24 sessions completed in 10-16 weeks, with two sessions per week. Individual 
sessions were 45 minutes in length (total treatment duration = 855-1080 minutes). PFPP proceeds in 
three phases. Phase I is focused on identifying the content and meaning of panic episodes, and any 
links between these episodes and experiences with caregivers, difficulty expressing/managing 
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feelings/fantasies, and any prior experiences of trauma/loss. Phase II addresses difficulties managing 
anger, abandonment fears, and separation situations, with links to panic episodes, through 
discussion of the patient’s feelings/fantasies about past/present relationships and in the 
transference relationship with the therapist. Phase III is focused on increasing emotional expression 
and assertiveness around conflicts that arise in the context of panic episodes and treatment 
termination.  
     Control participants were contacted by phone by a trial assessor every second week for a brief 
conversation about their general wellbeing and panic symptoms during the past week. No 
advice/intervention was provided during the conversations; the purpose was to provide a minimal 
level of support that would help the participant remain in the condition/trial until re-randomisation.  
Therapists 
Treatment was delivered by 45 therapists: PCT = 20 (12 women, 8 men); PFPP = 25 (17 women, 8 
men). Their basic professional training was: clinical psychology (n = 22; PCT = 10, PFPP = 12), social 
work (n = 16; PCT = 4; PFPP = 12), nursing (n = 2; PCT = 2), and other (social scientist, psychiatric 
healthcare) professional training (n = 5; PCT = 4, PFPP = 1). All therapists  completed a three-year, 
state-regulated/approved, post-graduate training course in either CBT or PDT, with 18 of the 45 
being further trained and licensed as psychotherapists by the National Board of Health and Welfare 
(PCT =4, PFPP = 14). Therapists had no affiliation to the authors or their employer. Compared to PCT 
therapists, the PFPP therapists had longer experience providing psychotherapy (PFPP = 15.4 years 
(SD = 9.1) vs. PCT = 8.7 years (SD = 4.4), p =.004), but PFPP and PCT therapists did not differ in the 
average number of PD/A patients treated before study participation (PCT = 3.4 (SD = 1.0) vs. PFPP = 
3.2 (SD = 1.3), p = .670).    
     Prior to delivering treatment in the trial, all therapists underwent group-based trainings in either 
PCT or PFPP, and then completed a supervised treatment case using the per-protocol manual with an 
adequate level of adherence. As therapists were recruited throughout the trial, four separate two-
day PCT/PFPP trainings were carried out. The first was delivered by Professors Barbara Milrod (PFPP) 
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and Michelle Craske (PCT), who also provided training to the trial supervisors (who worked 
throughout the length of the trial). Three further training courses in PFPP and PCT were carried out 
by HJ, GV, and SP. Approximately 120 therapists were trained but only 45 agreed to participate and 
were subsequently approved on at least one case per trial protocol and supervised during the entire 
trial.   
Treatment Adherence 
Two groups of graduate clinical psychology students (PCT = 5, PFPP = 3), trained to rate treatment 
adherence, rated one therapy session drawn from the beginning, middle and termination phase of 
treatment for every participant. PCT adherence was evaluated using a session-specific rating scale 
approved by Professor Craske, including 3-9 items (varying between sessions), each rated on a 7-
point Likert scale. A mean score ≥ 4 indicates satisfactory adherence. The inter-rater reliability 
coefficient (ICC) between the PCT adherence raters was ICC (2, 1) = .89. The mean adherence rating 
across all items and participants was 4.55 (SD = 0.73). PFPP adherence was rated using a session non-
specific scale approved by Professor Milrod, including seven items, each rated on a 7-point Likert 
scale. A score ≥ 4 on at least five items indicates adequate levels of adherence. For PFPP raters the 
ICC (2, 1) was .67. The mean adherence rating across all items and participants for PFPP was 4.88 (SD 
= 0.87).  
Outcome Assessor Training  
Given the widely dispersed geographical locations of the treatment sites, the number and length of 
the inclusion/outcome assessments, and the overall length of the trial, it was decided prior to the 
trial that it would be difficult to recruit and maintain blinded assessors who were external to the 
research group for the duration of the trial. It was also assumed that participants would be more 
willing to complete all assessments if they had the same assessor throughout the trial. Accordingly, 
all assessments were conducted by MS and TN. Both were trained to conduct diagnostic assessments 
and met regularly throughout the trial to maintain the quality and similarity of the assessment 
procedure across participants and sites. As the assessors were responsible for all inclusion and 
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outcome assessments, they were not blinded to condition. To control for possible rating bias, three 
masters-level clinical psychology students, external to the trial, were trained to assess the primary 
outcome variable using videotapes of trial assessments. For the post-treatment/control and follow-
up assessments, the internal assessor’s videotaped assessments did not include discussion of 
allocation or treatment status. From all five assessments (trial inclusion, post-treatment, 6-, 12- and 
24-month follow-up) a random sample of 264 videotapes of PDSS interviews were selected 
(representing > 25% of all interviews) and rated by the external assessors who were blinded to 
condition. The inter-rater reliability coefficient for total scores on the primary outcome measure 
between the internal and external assessors was ICC (2, 1) = .98. 
Measures 
Primary and secondary outcome measures were administered at trial inclusion, post-treatment, and 
the 6-, 12- and 24-month follow-up assessments. Diagnostic status (PD/A and comorbidity) was 
assessed via the Structured Clinical Interviews for DSM-IV [SCID-I and SCID-II; 24, 25]. Reliability for a 
PD/A diagnosis between MS and TN was computed as Kappa coefficient = 1.00 for agreement, based 
on ten videotaped SCID interviews.  
     Primary outcome measures: Consistent with recommendations for the evaluation of outcomes in 
treatment trials for PD/A, the clinician-rated Panic Disorder Severity Scale (PDSS) was chosen as the 
primary outcome measure [26]. The PDSS is a 7-item measure of the severity of the core features of 
PD over the past month [27]. Items are rated on a five-point scale (0 to 4) with higher scores 
indicating greater severity. The PDSS has excellent psychometric properties [28]. Responder status at 
post-treatment and follow-up was calculated as a > 40% reduction (relative to pre-treatment) on the 
PDSS [25]. Occupational status (Work) and the number of self-reported absences due to sickness 
(Absences) were included as additional primary outcomes owing to the explicit targets/outcomes 
identified as important by the government agency who funded part of this trial. Work was a 
dichotomised categorisation of the participant’s self-reported employment status. Absences was a 
dichotomised categorisation (0 weeks or > 1 week of absence from work during the last 3 months).  
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     Secondary outcome measures: The PDSS Self-Report version (PDSS-SR)3 contains the same 7 items 
and scoring system as the PDSS and possesses excellent psychometric properties [27]. In the present 
study, the correlation between the PDSS-SR and PDSS across treatment and follow-up was r = .86. 
The Mobility Inventory for Agoraphobia (MI) is a 4-item self-report measure of the degree of 
agoraphobic avoidance (1 = never, 5 = always) across 27 different situations, rated for when the 
individual is alone or accompanied [21]. A single, item-level average is computed. The Sheehan 
Disability Scale (SDS) is a 3-item self-report measure of the degree of functional impairment (0 = not 
all, 10 = extremely) in work, social life, and the family over the past week [29]. A single total score (0-
30) is computed. The 9-item self-report version of the Montgomery Åsberg Depression Rating Scale 
(MADRS-S) assesses the severity (0-6) of depressive symptoms over the past three days, with a single 
total score computed [30]. For adverse events, we recorded severe medical or psychiatric conditions, 
deaths from whatever cause, all self-harm and suicide attempts, and reliable worsening of symptoms 
as measured by the PDSS. All scales had acceptable internal consistency in the present sample 
(Cronbach´s alpha > .72). 
Sample size 
Power calculations were performed using Power IN Two-level designs (PINT v. 2.12, September 2007) 
[31] for change scores on the PDSS. Based on previous research on preference effects on the severity 
of psychiatric symptoms [6, 7], we assumed that the effect of allocation (choice vs. randomisation) 
would have a Standardized Mean Difference (SMD) = 0.40 on the PDSS post-treatment and during 
follow-up. Therefore, at alpha = 0.05, power = 0.80, and SMD = 0.40, 200 participants were required, 
with a planned recruitment of 221 to allow for attrition. 
Statistical Methods 
All analyses and reported outcomes follow the intention-to-treat (ITT) principle. Post-treatment 
differences for the PDSS for participants in each treatment arm versus Control were compared using 
                                                             
3 In the protocol paper PDSS-SR was, in contradiction to the clinical trials registration, erroneously labelled as a 
primary outcome. 
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one-way ANOVAs on unadjusted raw PDSS scores and post hoc analyses according to Dunnett’s 
method. Trajectory differences between the treatments in the Random (RPCT, RPFPP) and Choice 
conditions (CPCT, CPFPP) were examined using segmented multilevel linear growth modelling to 
handle nested and missing data. Outcome measures were modelled as functions of the number of 
months from baseline (0) until the 24-month follow-up (27), with a breakpoint at post-treatment (3). 
Linear, quadratic and log-linear trajectory shapes were compared using Akaike’s Information 
Criterion (AIC). For all outcome variables, the log-linear model yielded the smallest AIC value. 
Random intercepts and slopes for both time segments (baseline to post-treatment, post-treatment 
to 24-month follow-up) were estimated at both participant and therapist levels. Change in 
medication and additional treatment during the post-treatment to follow-up segments were added 
as time-dependent covariates with t-1 lags. Between-group differences on these variables were 
tested. The Missing at Random (MAR) assumption was tested using Pattern-Mixture Modeling [32] 
and revealed no violation of the MAR assumption (AIC increased slightly for the Pattern-Mixture 
model). Standardized mean differences (SMDs) were calculated according to Feingold [33] as the 
difference between treatments in model-estimated change from baseline, divided by the observed 
standard deviation at baseline across all groups. Chi-square tests were carried out for responder 
status and the two work-related variables. Data were analysed with SPSS (Version 26) and Stata 
(Version 16). 
Results 
Between November 2011 and May 2017, 604 adults were screened and 221 with a primary DSM-IV 
diagnosis of PD/A were included and randomised to the Choice, Random or Control conditions. Two 
participants randomised to the Control condition dropped out and two were excluded after 
completing it, leaving 217 participants available for randomisation to the Choice or Random 
conditions. Of the 109 participants randomised to Choice, 49 (45%) chose PCT and 60 (55%) chose 
PFPP (p = .341). The only significant difference between any of the groups at baseline was a higher 
Effect of patient’s choice of CBT or PDT 
 
13 
 
mean number of Axis I diagnoses (besides PD) in Randomised PFPP than in Randomised PCT (p =.028, 
corrected for family-wise error rate; see Table 1).  
     As shown in the Consort flow chart (Figure 1), 178 of the 217 participants (82%) randomised to the 
Choice and Random conditions completed treatment in accordance with the protocol. Five (2.3%) did 
not show up for treatment, 26 (11.8%) terminated prematurely on their own initiative, and 3 (1.4%) 
were withdrawn for reasons of safety (see serious adverse events below). Number of drop-
out/withdrawn cases did not vary by allocation (Choice vs. Random; p =.38) or treatment type (PCT 
vs PFPP; p =.93). PCT averaged 11.7 sessions, ranging between 60 and 120 minutes. PFPP averaged 
20.3 sessions, with a constant session length of 45 minutes. There was no association between PDSS 
outcome and number of sessions completed (p = .45).  There were no significant differences in the 
number of completers in the Choice and Random conditions, or between treatment types.  
Serious adverse events 
Serious adverse events during treatment were as follows: one participant (CPCT) suffered a non-trial-
related death; one participant (CPCT) experienced the onset of a severe medical illness, two 
participants were withdrawn for reasons of safety, one (CPCT) of them attempting suicide  and one 
(RPCT) experiencing a significant increase in symptoms of major depression; and two participants 
(RPCT and CPFPP) experienced significant worsening (>5.94) of panic symptoms according to the 
PDSS. 
Primary outcome measures 
Table 2 presents the mean raw scores for the PDSS at baseline and post-treatment for participants 
initially randomised to Choice, Random and Control conditions. Outcome differences between 
participants in the Control versus the Choice or Random conditions were both large and significant (p 
<.001). Choice: SMD = 1.74 (95% CI = 1.20 to 2.28); Random: SMD = 1.71 (95% CI = 1.17 to 2.26). Not 
reported in Table 2, the differences between treatment types within the Choice and Random 
conditions (CPCT, CPFPP, RPCT, and RPPP) and the Control condition were all large and highly 
significant. Table 3 presents the mean raw scores  for the primary (PDSS only) and secondary 
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outcome measures at baseline, post-treatment, and follow-ups, by condition (Choice versus Random) 
and treatment within condition (PCT vs PFPP).  
    Table 4 presents the SMDs between the Choice and Random conditions, between PCT and PFPP, 
and the allocation by treatment type interaction, based on the rate of change coefficients (b). Figure 
2 presents the modelled trajectories on the PDSS and secondary outcome measures for the 
treatment types within the Choice and Random conditions. Irrespective of choice versus random 
assignment to treatment or treatment type, steep decreases for the estimated scores on the PDSS 
occurred during treatment (mean b = -6.32, p <.001; 95% CI = -7.12 to -5.52; SMD = -1.53; 95% CI = -
1.72 to -1.34) and continued to decrease during the follow-up (mean b = -3.06, p <.001; 95% CI = -
3.91 to –2.21; SMD = -0.74; 95% CI =  -0.95 to -0.54). Accordingly, PDSS change from intake to follow-
up 27 months later was SMD = -2.27 (95%CI = -2.52 to -2.02). There was no significant effect of 
allocation (Choice vs. Random) during treatment or follow-up. Consistent with expectation, 
significantly larger reductions on the PDSS occurred for those receiving PCT than PFPP during 
treatment, but during follow-up the pattern was significantly reversed so that from baseline to the 
24-month follow-up, the two treatment types yielded similar outcomes. The allocation by treatment 
type by time interaction was not significant during treatment or follow-up. Not reported in Table 4, 
all comparisons for Work or Absences were non-significant during treatment or follow-up (all p’s > 
.485 for Work and > .327 for Absences). Neither change in medication, nor additional treatment 
differed significantly between the treatment groups at any time (p’s = .107 to .939).  
Secondary outcome measures 
For clinician-rated outcomes, the percentage of participants achieving a clinically significant response 
on the PDSS (i.e., > 40% reduction from pre-treatment scores) [26] at post-treatment and by the 24-
month follow-up were as follows: RPCT = 63.0% and 69.6%; RPFPP = 32.7% and 65.3%; CPCT = 56.8% 
and 61.4%; and CPFPP = 46.3% and 75.9%. The p value for between-group differences at post-
treatment was p = .018, and at ensuing follow-ups all between-group p’s were > .413. The proportion 
of participants who fell into the normal or borderline level of severity on the PDSS (total score ≤ 5) 
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[26] by the 24-month follow-up was as follows: RPCT = 49.1%; RPFPP = 38.2%; CPCT = 40.8%; and 
CPFPP = 55.0% (p = .416). 
    The secondary, self-reported outcomes showed the same pattern of effects as the clinician-rated 
PDSS, albeit of varying sizes (see Table 3). Again, the allocation effects (Choice vs. Random) were 
non-significant throughout. PCT produced steeper changes than PFPP during the treatment phase 
while the reverse was true during the follow-up phase. There were no significant allocation by 
treatment type by time interactions.  
Discussion  
Both theory and previous preference studies suggest that psychotherapy patients who receive their 
preferred treatment may experience better outcomes than either those not offered a treatment 
choice or who receive their non-preferred treatment. However, these studies have not employed 
designs that permit a rigorous test of this preference/choice-outcome relationship. The present 
study is the first doubly randomised controlled preference trial (DRCPT) to address these questions. 
The specific aim was to test whether giving patients with PD/A a choice between two evidence-based 
psychotherapies conferred an advantage over randomisation to these same treatments for PD/A 
severity, employment status, and absences from work. Contrary to expectation, and the small to 
moderate effects on symptoms of receiving one’s preferred treatment found in previous studies [7, 
2, 3], no such advantage was observed for clinician-rated PD/A severity in this study. In addition, 
there was no added benefit of choosing one’s preferred treatment on employment status or work 
absences. We also note that participants randomised to treatment were no less likely to drop-out of 
treatment than those who chose their treatment, in direct contrast to one of the reported benefits of 
providing patients choice of their treatment. While further DRCPTs are needed before firm 
conclusions can be drawn, in the context of the extant literature, the present findings suggest that 
treatment preference effects may be limited when the choice is between two evidenced-based 
psychotherapies when compared to psychotherapy versus medication.  
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     It is also possible that our failure to find any beneficial effect of choice versus random allocation to 
treatment lies in the choice of psychotherapies (PCT and PFPP) and the unexpected disordinal 
interaction between allocation and treatment type, the presence of which mitigates any main effect. 
Specifically, the positive RPFPP-CPFPP and the negative RPCT-CPCT differences tended to cancel one 
another out leaving the Choice-Random difference close to zero. A different set of findings may have 
emerged if the choice were between two other forms of evidence-based psychotherapy for PD/A. 
Importantly, this type of interaction (e.g., allocation by treatment type), which did not reach 
significance in this trial, requires significantly larger samples than used here [34]. The assumption at 
study planning was that the effect of choice would be in the same direction for both treatment types 
and the trial was powered to detect the main effect of choosing versus random allocation to 
treatment.  
     Consistent with hypotheses, treated participants experienced significantly greater reductions than 
controls at post-treatment, with PCT being superior to PFPP, but only during treatment. During the 
follow-up period, participants who received PFPP continued to improve more than those who 
received PCT, and this difference was not explained by receipt of additional treatments during the 
follow-up period, whether pharmaceutical or psychological. In addition, therapists delivering PFPP 
and PCT did not differ in terms of their prior experience of treating PD/A before the trial or in relation 
to treatment adherence during the trial; the latter being high for both treatment types. This finding 
provides a demonstration of the importance of long-term follow-ups in PD/A trials. The secondary 
outcomes (proportion of responders, self-reported PD severity, agoraphobia, depression, and 
disability) tended to show the same pattern of results as the primary outcome variable (clinician-
rated PD/A severity). A meta-analysis suggested that treatment preferences may exert stronger 
effects on non-targeted than targeted symptoms [2]. The present findings for depression, 
employment status, and work absences, do not appear to support such a conclusion.  
In addition to the literature on treatment preferences, the current trial adds important 
information to the broader literature on the effectiveness of psychological treatments for PD. The 
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trial was carried out in routine psychiatric care clinics, by therapists working in these services, and 
with patients who had a prior history of treatment for PD, and high levels of comorbidity. The 
investigators are not the original developers of the treatments under study, and included a mix of 
PDT and CBT researchers. While response rates for PCT were comparable to those reported in meta-
analyses [10], those for PFPP were somewhat lower than in the two RCTs carried out by the 
developers of that treatment [15, 17]. However, and in contrast to a previous trial comparing PFPP to 
PCT [35], participants receiving PFPP in this trial continued to improve for up to two years after 
treatment termination. This is only the fourth RCT to evaluate the efficacy of PDT for PD/A 
specifically, and provides further support for PFPP as a treatment for PD/A.  
With respect to limitations, this treatment outcome study conforms to the main 
recommendations for trial design by Guidi et al [19] with two exceptions: the use of a wait-list 
control group and non-blinded outcome assessments. While the present trial involved a wait-list 
control group, which are of limited utility for evaluating the efficacy of a particular treatment, the 
design involved comparisons between two active treatment conditions (random versus choice) and 
therapy types (PCT vs PFPP). Also, while outcomes were not blindly assessed, three external judges 
blindly rated a large sample of outcome interviews and obtained very high levels of agreement with 
the non-blinded assessors. A similar pattern of results was also obtained for the secondary, patient-
reported outcomes. Consistent with prior preference studies, written information sheets about the 
treatments were used to elicit choice. As noted above, we endeavoured to make the written 
presentations comparable in terms of detail, and this may have made the two treatments appear too 
similar or elicited unintended biases. The present trial involved the choice between PCT and PFPP, as 
representatives of CBT and PDT, because CBT and PDT are the two most widely used approaches 
used widely in routine care facilities throughout Sweden, and because they draw upon distinct 
theories of change and ways of working. A different set of findings may have emerged had we 
chosen two other forms of psychotherapy, or indeed different forms of CBT [36] and PDT (however, 
there are no other panic-specific forms of PDT). It is also important to point out that the findings 
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from this paper are based on mean scores for groups and there are likely important variations in 
outcomes for individuals. Outcome analysis at the individual level, for instance by multilevel latent 
class regression analysis, was beyond the scope of this paper and is the subject of future 
investigations. 
 Finally, as with outcomes in any RCT, other variables may interact with allocation to influence 
(predict or moderate) outcomes. Of particular relevance are the potential contribution of 
comorbidity (e.g., personality disorders) and medication usage [37]. In routine clinical practice, 
patients with PD/A are often assisted in tapering or withdrawing from medication during 
psychotherapy to facilitate emotional expression and symptom change, while in RCTs medication is 
usually held constant during the immediate pre-treatment and treatment phases to isolate the 
effects of allocation to the trial conditions. Preliminary analyses found no evidence that medication 
usage influenced outcomes in this trial. A full multivariate investigation of how patient variables 
influence both the choice of treatment and outcomes is the subject of separate papers.  
     This was the first DRCPT comparing two forms of psychotherapy for PD/A, and indeed any 
condition. Giving patients with PD/A the opportunity to choose one of two evidence-based 
treatments (psychotherapies) was not associated with improved outcomes over randomisation to 
treatment. The effect of choice of treatment appeared to be moderated by treatment type, but only 
in a positive direction for PFPP. Further DRCPTs, employing larger sample sizes, different treatments, 
and similarly long-term follow-ups are warranted. 
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Figure 1. Participant Flowchart. 
Abbreviations: PCT = Panic Control Treatment; PFPP = Panic-Focused Psychodynamic Psychotherapy; Control = 
Control condition; Part = Participants  
 
  
604 Screening 
253 Assessed for Eligibility 
221 Randomised 
351 Excluded at screening 
20 Exclusion diagnosis present 
109 Other primary disorder 
21 Unwilling to refrain from non-study treatment 
17 Psychotropic medication unstable 
86 insufficient panic severity 
5 Unwilling to risk phone-contact option 
54 Practical problems 
9 Inadequate language skills 
10 Did not show up for assessment interview 
20 Other 
 
 
 
32 Excluded at intake assessment 
4 Exclusion diagnosis present 
12 Other primary disorder 
9 Insufficient panic severity 
3 Inadequate language skills 
2 Practical problems 
2 Other 
 
108 Randomisation 
(101+9) 
21 Control 
19 (90%) Completed Control 
2 (10%) Dropped out 
19 (90%) Re-assessed 
2 (11%) Excluded after re-assessment 
     1 Insufficient panic severity 
     1 Psychotropic medication unstable 
 
 
     
      
 109 Choice 
(99+8) 
46 (87%) had post-treat. data 
44 (83%) had 6 month data 
44 (83%) had 12 month data 
42 (79%) had 24 month data 
 
54 (90%) had post-treat. data 
53 (88%) had 6 month data 
50 (83%) had 12 month data 
51 (85%) had 24 month data 
 
 
49 (89%) had post-treat. data 
44 (80%) had 6 month data 
42 (76%) had 12 month data 
39 (71%) had 24 month data 
 
 
53 PCT 
43 (81%) Completed treatment 
10 (19%) Dropped out 
     2 Never showed up 
     X Part medical condition 
     X Therapist medical condition 
     1 Withdrawn for safety 
     X Improved 
     X Part dies 
     7 Unspecified 
55 PFPP 
44 (80%) Completed treatment 
11 (20%) Dropped out 
     X Never showed up 
     X Part medical condition 
     2 Therapist medical condition 
     X Withdrawn for safety 
     1 Improved 
     X Part dies 
     8 Unspecified 
 
49 PCT 
37 (76%) Completed treatment 
12 (24%) Dropped out 
     2 Never showed up 
     1 Part medical condition 
     X Therapist medical condition 
     1 Withdrawn for safety 
     1 Improved 
     1 Part dies 
     6 Unspecified 
 
 
60 PFPP 
54 (90%) Completed treatment 
6 (10%) Dropped out 
     1 Never showed up 
     X Part medical condition 
     X Therapist medical condition 
     X Withdrawn for safety 
     X Improved 
     X Part dies 
     5 Unspecified 
 
44 (90%) had post-treat. data 
41 (84%) had 6 month data 
41 (84%) had 12 month data 
40 (82%) had 24 month data 
   
 
17 Re-randomisation 
9 Randomisation 
8 Choice 
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Figure 2. Modelled trajectories, with 95% confidence intervals, on the PDSS and the secondary outcome 
measures for the therapy types within the Choice and Random conditions 
Abbreviations: 0 = Baseline; 3 = Post-treatment; 9 = 6 months follow-up; 15 = 12 months follow-up; 27 = 24 
months follow-up. 
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Table 1. Baseline characteristics by condition 
  After Re-Randomization  
  Randomised condition Choice condition  
 
Total 
(n=221) 
RPCT 
(n=53) 
RPFPP 
(n=55) 
CPCT 
(n=49) 
CPFPP 
(n=60) 
Control* 
(n=21) 
Demographics, n, %       
Female 165 (74.7) 40 (75.5) 40 (72.7) 34 (69.4) 49 (81.7) 14 (66.7) 
Basic level education 23 (10.4) 6 (11.5) 7 (12.7) 3 (6.1) 5 (8.5) 2 (9.5) 
High school 114 (51.6) 28 (53.8) 31 (56.4) 27 (55.1) 27 (45.8) 11 (52.4) 
University education 82 (37.1) 18 (34.6) 17 (30.9) 19 (38.8) 27 (45.8) 8 (38.1) 
Employed 193 (87.3) 43 (82.7) 49 (89.1) 43 (89.6) 54 (90.0) 14 (66.7) 
Age at entry, years, M, SD 34.9 (12.6) 34.4 (13.9) 35.3 (13.1) 36.8 (13) 33 (10.4) 36.7 (13.6) 
Current Psychiatric Conditions, n, %       
PD with agoraphobia 184 (83.3) 41 (77.4) 45 (81.1) 43 (87.8) 51 (85.0) 18 (85.7) 
PD without agoraphobia 37 (16.7) 12 (22.6) 10 (18.2) 6 (12.2) 9 (15.0) 3 (14.3) 
Any Axis I diagnosis besides PD/PDA 156 (70.6) 30 (56.6) 40 (72.7) 37 (75.5) 48 (80.0) 13 (61.9) 
Any personality disorder 52 (23.5) 10 (18.9) 15 (27.3) 11 (22.4) 16 (26.7) 3 (14.3) 
No. of Axis I diagnoses besides PD/PDA, M, SD 1.7 (1.7) 1.2 (1.4) 2.1 (2.1) 1.6 (1.4) 1.8 (1.5) 1.6 (2.2) 
Clinical characteristics       
Panic debut, months, Md, IQR 72 (144) 48 (84) 96 (204) 96 (143) 74 (113) 120 (198) 
Panic episode, months, Md, IQR 10 (29) 6 (18) 9 (34) 18 (80) 12 (26) 6 (21) 
PDSS, M, SD 15.6 (4.1) 14.9 (3.8) 15.9 (3.8) 16.1 (4.7) 15.5 (4.1) 16.8 (4.7) 
Previous psychotherapy, n, % 136 (61.5) 32 (64.0) 39 (70.9) 28 (59.6) 35 (58.3) 14 (66.7) 
Psychotropic medication use, n, % 117 (53.4) 27 (50.9) 29 (51.7) 31 (63.3) 27 (45.0) 14 (66.7) 
Note. R = Randomised condition; C = Choice condition; PFPP = Panic-Focused Psychodynamic Psychotherapy; PCT = Panic Control 
Treatment; Control = Control condition; PDSS = Panic Disorder Severity Scale; Md = Median; IQR = Inter Quartile Range 
 
*Re-randomised after completed Control condition and re-assessment of eligibility 
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Table 2. Raw scores for Control, Randomised and Choice condition 
  Control n Random n Choice n 
PDSS, M, SD Baseline 16.8 (4.7) 21 15.5 (3.9) 99 15.5 (4.2) 101 
 Post-treatment 16.4 (5.0) 19 9.2 (5.6) 87 9.1 (4.6) 93 
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Table 3. Raw Scores by Treatment Conditions and Time of Assessment 
  RPCT n RPFPP n CPCT n CPFPP n 
PDSS, M, SD Baseline 14.9 (3.8) 53 15.7 (4.1) 55 16.0 (4.6) 49 15.5 (4.1) 60 
 Post-treatment 7.5 (4.8) 46 10.8 (5.9) 49 8.6 (4.1) 44 9.7 (5.5) 54 
 6 mos follow-up 6.4 (5.4) 44 8.4 (5.5) 44 8.4 (5.5) 41 7.8 (5.3) 53 
 12 mos follow-up 5.9 (4.7) 44 8.5 (6.1) 42 8.3 (5.9) 41 6.4 (5.2) 50 
 24 mos follow-up 6.2 (5.3) 42 7.5 (5.6) 39 7.1 (5.9) 40 5.1 (5.1) 51 
Work, % Baseline 17.3 52 12.7 55 8.3 48 12.1 60 
 Post-treatment 11.4 44 10.2 49 11.9 42 9.4 53 
 6 mos follow-up 11.4 44 11.9 42 14.6 41 5.7 53 
 12 mos follow-up 9.5 42 17.1 41 12.5 40 4.0 50 
 24 mos follow-up 13.2 38 14.3 35 15.8 38 6.4 47 
Absence, % Baseline 13.5 52 23.6 55 24.5 49 19.0 58 
 Post-treatment 13.6 44 21.3 47 16.7 42 23.1 52 
 6 mos follow-up 9.3 43 19.5 41 14.6 41 22.6 53 
 12 mos follow-up 10.0 40 25.6 39 10.3 39 12.0 50 
 24 mos follow-up 10.8 37 17.6 34 15.8 38 19.1 47 
PDSS-SR, M, SD Baseline 11.9 (4.5) 52 12.8 (4.6) 55 12.6 (4.9) 49 12.4 (4.2) 60 
 Post-treatment 4.1 (4.2) 44 7.6 (5.9) 49 4.5 (4.3) 42 6.7 (5.6) 54 
 6 mos follow-up 3.2 (4.0) 44 5.4 (4.6) 42 4.9 (5.1) 41 5.6 (5.3) 53 
 12 mos follow-up 3.1 (3.5) 42 5.8 (5.6) 41 4.8 (4.7) 40 4.4 (4.5) 50 
 24 mos follow-up 3.0 (3.8) 39 4.2 (5.1) 37 3.5 (5.3) 38 3.3 (4.0) 47 
SDS, M, SD Baseline 14.6 (6.5) 52 14.1 (6.3) 55 15.0 (6.3) 49 14.6 (6.1) 60 
 Post-treatment 6.7 (6.6)  44 9.7 (7.7) 49 6.0 (6.9) 42 9.3 (8.0) 54 
 6 mos follow-up 5.3 (7.2) 44 7.7 (6.9) 42 5.6 (7.1) 41 6.9 (6.4) 53 
 12 mos follow-up 4.3 (5.3) 42 6.5 (7.5) 41 6.2 (7.6) 40 5.1 (6.6) 50 
 24 mos follow-up 3.7 (5.8) 39 5.7 (6.9) 37 5.2 (7.1) 38 4.7 (6.6) 47 
MI, M, SD Baseline 2.2 (0.8) 52 2.4 (0.8) 55 2.3 (0.7) 49 2.1 (0.7) 60 
 Post-treatment 1.6 (0.6) 44 2.0 (0.8) 49 1.6 (0.5) 42 1.8 (0.7) 54 
 6 mos follow-up 1.6 (0.7) 44 1.8 (0.8) 42 1.7 (0.6) 41 1.6 (0.7) 53 
 12 mos follow-up 1.5 (0.7) 42 1.7 (0.7) 41 1.6 (0.6) 40 1.5 (0.6) 50 
 24 mos follow-up 1.5 (0.6) 39 1.8 (0.9) 37 1.5 (0.5) 38 1.4 (0.5) 47 
MADRS-S, M, SD Baseline 17.7 (8.1) 52 17.0 (8.0) 55 17.3 (9.2) 49 18.0 (7.7) 60 
 Post-treatment 10.4 (8.8) 44 12.0 (8.7) 49 9.2 (7.6) 42 11.8 (8.5) 54 
 6 mos follow-up 9.7 (8.8) 44 11.7 (8.8) 42 10.2 (6.7) 41 10.2 (7.7) 53 
 12 mos follow-up 8.6 (8.3) 42 10.5 (8.2) 41 9.9 (7.9) 40 9.2 (7.1) 50 
 24 mos follow-up 8.7 (8.5) 39 8.9 (8.5) 37 10.4 (8.2) 38 8.5 (7.4) 47 
Note. R = Randomised condition; C = Choice condition; PFPP = Panic-Focused Psychodynamic 
Psychotherapy; PCT = Panic Control Treatment; PDSS = Panic Disorder Severity Scale; PDSS-SR = Panic 
Disorder Severity Scale, Self-Rating; MI = Mobility Inventory for Agoraphobia; SDS = Sheehan Disability 
Scale; MADRS-S = Montgomery Asberg Depression Rating Scale 
 
*Re-randomised after completed Control condition and re-assessment of eligibility 
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Table 4. Effect Sizes (Standardized Mean Differences; SMDs) of Differential Change, by Treatment Contrasts and Time Segments 
(Confidence Intervals in Parentheses) 
 
 
 
 
Outcome 
Measure 
Segment/Months C-R PFPP- PCT 
(RPFPP - CPFPP) – 
(RPCT - CPCT) 
RPFPP - RPCT 
PDSS Baseline to Post-treatment 0.03 (-0.26 to 0.33) -0.64 (-1.02 to -0.25) -0.29 (-0.88 to 0.30) -0.78 (-1.27 to -0.30) 
 Post-treatment to 24 mos 0.08 (-0.26 to 0.42) 0.62 (0.27 to 0.98) -0.28 (-0.96 to 0.41) 0.48 (-0.02 to 0.98) 
 Baseline to 24 mos 0.11 (-0.26 to 0.48) -0.01 (-0.47 to 0.44) -0.57 (-1.31 to 0.17) -0.30 (-0.89 to 0.29) 
PDSS-SR Baseline to Post-treatment 0.00 (-0.32 to 0.32) -0.56 (-0.89 to -0.22) -0.22 (-0.86 to 0.42) -0.67 (-1.13 to -0.20) 
 Post-treatment to 24 mos 0.04 (-0.25 to 0.33) 0.40 (0.11 to 0.69) -0.12 (-0.70 to 0.46) 0.34 (-0.07 to 0.76) 
 Baseline to 24 mos 0.04 (-0.27 to 0.34) -0.15 (-0.48 to 0.17) -0.34 (-0.95 to 0.27) -0.32 (-0.77 to 0.13) 
SDS Baseline to Post-treatment 0.08 (-0.19 to 0.36) -0.53 (-0.80 to -0.25) -0.01 (-0.56 to 0.54) -0.54 (-0.93 to -0.14) 
 Post-treatment to 24 mos -0.09 (-0.37 to 0.19) 0.37 (0.09 to 0.65) -0.36 (-0.92 to 0.20) 0.19 (-0.22 to 0.59) 
 Baseline to 24 mos -0.01 (-0.29 to 0.27) -0.16 (-0.44 to 0.11) -0.37 (-0.93 to 0.18) -0.35 (-0.75 to 0.05) 
MI Baseline to Post-treatment 0.03 (-0.27 to 0.22) -0.49 (-0.73 to -0.25) 0.24 (-0.24 to 0.72) -0.37 (-0.71 to -0.03) 
 Post-treatment to 24 mos 0.11 (-0.12 to 0.33) 0.27 (0.02 to 0.51) -0.24 (-0.68 to 0.20) 0.15 (-0.18 to 0.48) 
 Baseline to 24 mos 0.08 (-0.21 to 0.37) -0.22 (-0.53 to 0.09) -0.00 (-0.59 to 0.58) -0.22 (-0.65 to 0.21) 
MADRS-S Baseline to Post-treatment 0.11 (-0.18 to 0.40) -0.26 (-0.55 to 0.02) -0.19 (-0.77 to 0.38) -0.36 (-0.77 to 0.05) 
 Post-treatment to 24 mos -0.14 (-0.44 to 0.15) 0.29 (-0.01 to 0.58) -0.33 (-0.92 to 0.26) 0.13 (-0.30 to 0.55) 
 Baseline to 24 mos -0.03 (-0.32 to 0.25) 0.03 (-0.26 to 0.31) -0.52 (-1.10 to 0.05) -0.24 (-0.65 to 0.18) 
Note. R = Randomised condition; C = Choice condition; PFPP = Panic-Focused Psychodynamic Psychotherapy; PCT = Panic Control 
Treatment; PDSS = Panic Disorder Severity Scale; PDSS-SR = Panic Disorder Severity Scale, Self-Rating; MI = Mobility Inventory for 
Agoraphobia; SDS = Sheehan Disability Scale; MADRS-S = Montgomery Asberg Depression Rating Scale; 24 mos = 24 month follow-up 
 
 
